BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38594917)

  • 21. Identification and analysis of prognostic immune cell homeostasis characteristics in lung adenocarcinoma.
    Sun Y; Ma Q; Chen Y; Liao D; Kong F
    Clin Respir J; 2024 May; 18(5):e13755. PubMed ID: 38757752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
    Zhou J; Wang X; Li Z; Jiang R
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 25. A promising prognostic signature for lung adenocarcinoma (LUAD) patients basing on 6 hypoxia-related genes.
    Luo J; Du X
    Medicine (Baltimore); 2021 Dec; 100(50):e28237. PubMed ID: 34918689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A gene expression-based immune signature for lung adenocarcinoma prognosis.
    Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
    Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
    Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
    Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma.
    Xiao L; Li Q; Huang Y; Fan Z; Ma L; Liu B; Yuan X
    J Healthc Eng; 2022; 2022():7651758. PubMed ID: 35251577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
    BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
    Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
    J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a four-gene panel predicting overall survival for lung adenocarcinoma.
    Li C; Long Q; Zhang D; Li J; Zhang X
    BMC Cancer; 2020 Dec; 20(1):1198. PubMed ID: 33287749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
    Sui P; Liu X; Zhong C; Sha Z
    Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.